. 2022 Dec 26;11(1):4. doi: 10.3390/medsci11010004

Table 2.

Study characteristics. NOTE: RCT, randomized controlled trial; CRP-C, reactive protein; Vo2, peak oxygen consumption; VE/Vco2, minute ventilation–carbon dioxide production slope; NT, proBNP-N-terminal pro-B-type natriuretic peptide; AEs, adverse events; QoL, quality of life; CPX, cardiopulmonary exercise testing.

Study ID		Participants			Anakinra (Once/Twice Daily Subcutaneous Injections) (mg)	Treatment Period (weeks)	Placebo (N)	Main Outcome Anakinra Effects
Author, year	Design	N	M/F	Age (years)	Anakinra (Once/Twice Daily Subcutaneous Injections) (mg)	Treatment Period (weeks)	Placebo (N)	Main Outcome Anakinra Effects
Abbate et al. (2020) [26]	RCT	99	80/19	45–65	100	2	35	AEs, CRP, stroke volume, and stroke work.
Abbate et al. (2022) [27]	RCT	139	110/29	48–61	100	2	55	CRP and AEs
Del Buono et al. (2022) [19]	RCT	99	80/19	48–65	100	2	35	CRP, leukocyte differential count
Van Tassell et al. (2014) [28]	RCT	12	1/11	62	100	4	6	CRP, VO₂, VE/VCO₂ slope, and exercise
Van Tassell et al. (2016) [29]	RCT	30	21/9	49–66	100	2	15	CRP, AEs, and NTproBNP
Van Tassell et al. (2017) [30]	RCT	60	38/22	49–68	100	12	18	AEs, QoL, CRP, NT-proBNP levels, VE/Vco₂ slope, and peak Vo₂.
Van Tassell et al. (2018) [31]	RCT	31	13/18	50–60	100	12	10	CRP levels, AEs, NT-proBNP levels, peak Vo₂ or the VE/Vco₂ slope, and exercise.
Van Tassell et al. (2022) [32]	RCT	102	_	≥21	100	24	34	CRP, CPX, peak VO₂, and QoL